<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00367133</url>
  </required_header>
  <id_info>
    <org_study_id>NEI-105</org_study_id>
    <secondary_id>U10EY018817-03</secondary_id>
    <secondary_id>U10EY014229-07</secondary_id>
    <secondary_id>U10EY014231-09</secondary_id>
    <nct_id>NCT00367133</nct_id>
  </id_info>
  <brief_title>Intravitreal Triamcinolone Acetonide Versus Laser for Diabetic Macular Edema</brief_title>
  <acronym>IVT</acronym>
  <official_title>A Randomized Trial Comparing Intravitreal Triamcinolone Acetonide and Laser Photocoagulation for Diabetic Macular Edema</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jaeb Center for Health Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Eye Institute (NEI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Jaeb Center for Health Research</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study involves the enrollment of patients over 18 years of age with diabetic macular
      edema(DME). Patients with one study eye will be randomly assigned (stratified by visual
      acuity and prior laser) with equal probability to one of the three treatment groups:

        1. Laser photocoagulation

        2. 1mg intravitreal triamcinolone acetonide injection

        3. 4mg intravitreal triamcinolone acetonide injection

      For patients with two study eyes (both eyes eligible at the time of randomization), the right
      eye (stratified by visual acuity and prior laser) will be randomly assigned with equal
      probabilities to one of the three treatment groups listed above. The left eye will be
      assigned to the alternative treatment (laser or triamcinolone). If the left eye is assigned
      to triamcinolone, then the dose (1mg or 4 mg) will be randomly assigned to the left eye with
      equal probability (stratified by visual acuity and prior laser).

      The study drug, triamcinolone acetonide, has been manufactured as a sterile intravitreal
      injectable by Allergan. Study eyes assigned to an intravitreal triamcinolone injection will
      receive a dose of either 1mg or 4mg. There is no indication of which treatment regimen will
      be better.

      Patients enrolled into the study will be followed for three years and will have study visits
      every 4 months after receiving their assigned study treatment. In addition, standard of care
      post-treatment visits will be performed at 4 weeks after each intravitreal injection.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Diabetic retinopathy is a major cause of visual impairment in the United States. Diabetic
      macular edema (DME) is a manifestation of diabetic retinopathy that produces loss of central
      vision. Data from the Wisconsin Epidemiologic Study of Diabetic Retinopathy (WESDR) estimate
      that after 15 years of known diabetes, the prevalence of diabetic macular edema is
      approximately 20% in patients with type 1 diabetes mellitus (DM), 25% in patients with type 2
      DM who are taking insulin, and 14% in patients with type 2 DM who do not take insulin.

      In a review of three early studies concerning the natural history of diabetic macular edema,
      Ferris and Patz found that 53% of 135 eyes with diabetic macular edema, presumably all
      involving the center of the macula, lost two or more lines of visual acuity over a two year
      period. In the Early Treatment Diabetic Retinopathy Study (ETDRS), 33% of 221 untreated eyes
      available for follow-up at the 3-year visit, all with edema involving the center of the
      macula at baseline, had experienced a 15 or more letter decrease in visual acuity score
      (equivalent to a doubling of the visual angle, e.g., 20/25 to 20/50, and termed &quot;moderate
      visual acuity loss&quot;).

      In the ETDRS, focal/grid photocoagulation of eyes with clinically significant macular edema
      (CSME) reduced the risk of moderate visual loss by approximately 50% (from 24% to 12%, three
      years after initiation of treatment). Therefore, 12% of treated eyes developed moderate
      visual loss in spite of treatment. Furthermore, approximately 40% of treated eyes that had
      retinal thickening involving the center of the macula at baseline still had thickening
      involving the center at 12 months, as did 25% of treated eyes at 36 months.

      Although several treatment modalities are currently under investigation, the only
      demonstrated means to reduce the risk of vision loss from diabetic macular edema are laser
      photocoagulation, as demonstrated by the ETDRS, and intensive glycemic control, as
      demonstrated by the Diabetes Control and Complications Trial (DCCT) and the United Kingdom
      Prospective Diabetes Study (UKPDS). In the DCCT, intensive glucose control reduced the risk
      of onset of diabetic macular edema by 23% compared with conventional treatment. Long-term
      follow-up of patients in the DCCT show a sustained effect of intensive glucose control, with
      a 58% risk reduction in the development of diabetic macular edema for the DCCT patients
      followed in the Epidemiology of Diabetes Interventions and Complications Study.

      The frequency of an unsatisfactory outcome following laser photocoagulation in some eyes with
      diabetic macular edema has prompted interest in other treatment modalities. One such
      treatment is pars plana vitrectomy. These studies suggest that vitreomacular traction, or the
      vitreous itself, may play a role in increased retinal vascular permeability. Removal of the
      vitreous or relief of mechanical traction with vitrectomy and membrane stripping may be
      followed by substantial resolution of macular edema and corresponding improvement in visual
      acuity. However, this treatment may be applicable only to a specific subset of eyes with
      diabetic macular edema. It also requires a complex surgical intervention with its inherent
      risks, recovery time, and expense. Other treatment modalities such as pharmacologic therapy
      with oral protein kinase C inhibitors and antibodies targeted at vascular endothelial growth
      factor (VEGF) are under investigation. The use of intravitreal corticosteroids is another
      treatment modality that has generated recent interest.

      The optimal dose of corticosteroid to maximize efficacy with minimum side effects is not
      known. A 4mg dose of Kenalog is principally being used in clinical practice. However, this
      dose has been used based on feasibility rather than scientific principles.

      There is also experience using Kenalog doses of 1mg and 2mg. These doses anecdotally have
      been reported to reduce the macular edema. There is a rationale for using a dose lower than
      4mg. Glucocorticoids bind to glucocorticoid receptors in the cell cytoplasm, and the
      steroid-receptor complex moves to the nucleus where it regulates gene expression. The
      steroid-receptor binding occurs with high affinity (low dissociation constant (Kd) which is
      on the order of 5 to 9 nanomolar). Complete saturation of all the receptors occurs about
      20-fold higher levels, i.e., about 100-200 nanomolar. A 4mg dose of triamcinolone yields a
      final concentration of 7.5 millimolar, or nearly 10,000-fold more than the saturation dose.
      Thus, the effect of a 1mg dose may be equivalent to that of a 4mg dose, because compared to
      the 10,000-fold saturation, a 4-fold difference in dose is inconsequential. It is also
      possible that higher doses of corticosteroid could be less effective than lower doses due to
      down-regulation of the receptor. The steroid implant studies provide additional justification
      for evaluating a lower dose, a 0.5mg device which delivers only 0.5 micrograms per day has
      been observed to have a rapid effect in reducing macular edema.

      There has been limited experience using doses greater than 4mg. Jonas' case series reported
      results using a 25mg dose. However, others have not been able to replicate this dose using
      the preparation procedure described by Jonas.

      In the trial, 4mg and 1mg doses will be evaluated. The former will be used because it is the
      dose that is currently most commonly used in clinical practice and the latter because there
      is reasonable evidence for efficacy and the potential for lower risk. Although there is good
      reason to believe that a 1mg dose will reduce the macular edema, it is possible that the
      retreatment rate will be higher with this dose compared with 4mg since the latter will remain
      active in the eye for a longer duration than the former. Insufficient data are available to
      warrant evaluating a dose higher than 4mg at this time.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2004</start_date>
  <completion_date type="Actual">October 2008</completion_date>
  <primary_completion_date type="Actual">May 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change In Visual Acuity [Measured With Electronic-Early Treatment Diabetic Retinopathy Study (E-ETDRS)]Baseline to 2 Years.</measure>
    <time_frame>Baseline to 2 Years</time_frame>
    <description>Change in best correct visual acuity letter score as measured by a certified tester using an electronic visual acuity testing machine based on the Early Treatment Diabetic Retinopathy Study (ETDRS) method. A positive change denotes an improvement. Best value on the scale 97, worst 0.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Median Change in Visual Acuity Baseline to 2 Years</measure>
    <time_frame>Baseline to 2 Years</time_frame>
    <description>Change in best correct visual acuity letter score as measured by a certified tester using an electronic visual acuity testing machine based on the Early Treatment Diabetic Retinopathy Study (ETDRS) method. A positive change denotes an improvement.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Distribution of Change in Visual Acuity Baseline to 2 Years</measure>
    <time_frame>baseline to 2 years</time_frame>
    <description>Change in best correct visual acuity letter score as measured by a certified tester using an electronic visual acuity testing machine based on the Early Treatment Diabetic Retinopathy Study (ETDRS) method.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Central Subfield Thickness at 2 Years</measure>
    <time_frame>2 Years</time_frame>
    <description>Median central subfield thickness at two-years. Optical coherence Tomography (OCT) images were obtained by a certified operator using the Zeiss Stratus OCT machine. If the automated thickness measurements were judged by the reading center to be inaccurate, center point thickness was measured manually, and this value was used to impute a value for the central subfield.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change in Central Subfield Thickness Baseline to 2 Years</measure>
    <time_frame>Baseline to 2 years</time_frame>
    <description>Overall central subfield change from baseline. Optical coherence Tomography (OCT) images were obtained by a certified operator using the Zeiss Stratus OCT machine. The average of 2 baseline central subfield thickness measurements was used for analysis.If the automated thickness measurements were judged by the reading center to be inaccurate, center point thickness was measured manually, and this value was used to impute a value for the central subfield. Negative change denotes and improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Change in Central Subfield Thickness Baseline to 2 Years</measure>
    <time_frame>Baseline to 2 Years</time_frame>
    <description>Overall central subfield change from baseline. Optical coherence Tomography (OCT) images were obtained by a certified operator using the Zeiss Stratus OCT machine. The average of 2 baseline central subfield thickness measurements was used for analysis.If the automated thickness measurements were judged by the reading center to be inaccurate, center point thickness was measured manually, and this value was used to impute a value for the central subfield. Negative change denotes an improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Central Subfield Thickening Decreased by &gt;=50% Baseline to 2 Years</measure>
    <time_frame>Baseline to 2 Years</time_frame>
    <description>Overall central subfield change from baseline. Optical coherence Tomography (OCT) images were obtained by a certified operator using the Zeiss Stratus OCT machine. If the automated thickness measurements were judged by the reading center to be inaccurate, center point thickness was measured manually, and this value was used to impute a value for the central subfield.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Central Subfield Thickness &lt; 250 Microns at 2 Years</measure>
    <time_frame>2 Years</time_frame>
    <description>Overall central subfield change from baseline. Optical coherence Tomography (OCT) images were obtained by a certified operator using the Zeiss Stratus OCT machine. If the automated thickness measurements were judged by the reading center to be inaccurate, center point thickness was measured manually, and this value was used to impute a value for the central subfield.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Visual Acuity From Baseline to 3 Years</measure>
    <time_frame>Baseline to 3 year</time_frame>
    <description>Change in best correct visual acuity letter score as measured by a certified tester using an electronic visual acuity testing machine based on the Early Treatment Diabetic Retinopathy Study (ETDRS) method. A positive change denotes an improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Visual Acuity From Baseline to 3 Years</measure>
    <time_frame>Baseline to 3 year</time_frame>
    <description>Change in best correct visual acuity letter score as measured by a certified tester using an electronic visual acuity testing machine based on the Early Treatment Diabetic Retinopathy Study (ETDRS) method. A positive change denotes an improvement. Best Value on the scale=97, Worst Value=0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distribution of Visual Acuity Change Baseline to 3 Years</measure>
    <time_frame>Baseline to 3 years</time_frame>
    <description>Change in best correct visual acuity letter score as measured by a certified tester using an electronic visual acuity testing machine based on the Early Treatment Diabetic Retinopathy Study (ETDRS) method. A positive change denotes an improvement. Best value on the scale=97, worst=0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Central Subfield Thickness on Optical Coherence Tomography (OCT) at Three Years</measure>
    <time_frame>3 years</time_frame>
    <description>Overall central subfield change from baseline. Optical coherence Tomography (OCT) images were obtained by a certified operator using the Zeiss Stratus OCT machine. If the automated thickness measurements were judged by the reading center to be inaccurate, center point thickness was measured manually, and this value was used to impute a value for the central subfield.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Central Subfield Thickness on OCT Baseline to 3 Years</measure>
    <time_frame>Baseline to 3 years</time_frame>
    <description>Overall central subfield change from baseline. Optical coherence Tomography (OCT) images were obtained by a certified operator using the Zeiss Stratus OCT machine. The average of 2 baseline central subfield thickness measurements was used for analysis.If the automated thickness measurements were judged by the reading center to be inaccurate, center point thickness was measured manually, and this value was used to impute a value for the central subfield. Negative change denotes an improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Eyes With a Change in Central Subfield Thickness on OCT &lt;250 Microns From Baseline to 3 Years</measure>
    <time_frame>Baseline to 3 years</time_frame>
    <description>Overall central subfield change from baseline. Optical coherence Tomography (OCT) images were obtained by a certified operator using the Zeiss Stratus OCT machine. The average of 2 baseline central subfield thickness measurements was used for analysis.If the automated thickness measurements were judged by the reading center to be inaccurate, center point thickness was measured manually, and this value was used to impute a value for the central subfield. Negative change denotes an improvement.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">840</enrollment>
  <condition>Diabetic Macular Edema</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard of care group: conventional treatment consisting of focal/grid photocoagulation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravitreal injection of 1mg of triamcinolone acetonide</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravitreal injection of 4mg of triamcinolone acetonide</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Standard of Care Group</intervention_name>
    <description>Standard of care group: conventional treatment consisting of focal/grid photocoagulation.</description>
    <arm_group_label>1</arm_group_label>
    <other_name>soc with laser</other_name>
    <other_name>modified ETDRS photocoagulation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>1mg triamcinolone acetonide</intervention_name>
    <description>Intravitreal injection of 1mg of triamcinolone acetonide at baseline. At each 4-month interval visit, the investigator will assess whether persistent or recurrent DME is present that warrants retreatment with the randomization assigned treatment. Retreatment, when indicated, will be performed within four weeks after the follow-up visit. Retreatment should not be performed sooner than 3.5 months from the time of the last treatment.</description>
    <arm_group_label>2</arm_group_label>
    <other_name>corticosteroid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>4mg triamcinolone acetonide</intervention_name>
    <description>4mg intravitreal triamcinolone acetonide injection at baseline. At each 4-month interval visit, the investigator will assess whether persistent or recurrent DME is present that warrants retreatment with the randomization assigned treatment. Retreatment, when indicated, will be performed within four weeks after the follow-up visit. Retreatment should not be performed sooner than 3.5 months from the time of the last treatment.</description>
    <arm_group_label>3</arm_group_label>
    <other_name>corticosteroid</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        To be eligible, the following inclusion criteria must be met:

          1. Age ≥18 years

          2. Diagnosis of diabetes mellitus (type 1 or type 2)

          3. Able and willing to provide informed consent.

          4. Patient understands that (1) if both eyes are eligible at the time of randomization,
             one eye will receive intravitreal triamcinolone acetonide and one eye will receive
             laser, and (2) if only one eye is eligible at the time of randomization and the fellow
             eye develops DME later, then the fellow eye will not receive intravitreal
             triamcinolone acetonide if the study eye received intravitreal triamcinolone acetonide
             (however, if the study eye was assigned to the laser group, then the fellow eye may be
             treated with the 4mg dose of the study intravitreal triamcinolone acetonide
             formulation, provided the eye assigned to laser has not received an intravitreal
             injection; such an eye will not be a &quot;study eye&quot; but since it is receiving study drug,
             it will be followed for adverse effects).

        Exclusion Criteria

        A patient is not eligible if any of the following exclusion criteria are present:

        7. History of chronic renal failure requiring dialysis or kidney transplant.

        8. A condition that, in the opinion of the investigator, would preclude participation in
        the study (e.g., unstable medical status including blood pressure and glycemic control).
        Note: Patients in poor glycemic control who, within the last 4 months, initiated intensive
        insulin treatment (a pump or multiple daily injections) or plan to do so in the next 4
        months should not be enrolled.

        9. Participation in an investigational trial within 30 days of study entry that involved
        treatment with any drug that has not received regulatory approval at the time of study
        entry.

        10. Known allergy to any corticosteroid or any component of the delivery vehicle.

        11. History of systemic (e.g., oral, IV, IM, epidural, bursal) corticosteroids within 4
        months prior to randomization or topical, rectal, or inhaled corticosteroids in current use
        more than 2 times per week.

        12. Patient is expecting to move out of the area of the clinical center to an area not
        covered by another clinical center during the 3 years of the study.

        13. Blood pressure &gt; 180/110 (systolic above 180 OR diastolic above 110). Note: If blood
        pressure is brought below 180/110 by anti-hypertensive treatment, patient can become
        eligible.

        Study Eye Eligibility

        Inclusion

          1. Best corrected Electronic-Early Treatment Diabetic Retinopathy Study (e-ETDRS) visual
             acuity score of ≥ 24 letters (i.e., 20/320 or better) and ≤73 letters (i.e., 20/40 or
             worse).

          2. Definite retinal thickening due to diabetic macular edema based on clinical exam
             involving the center of the macula.

          3. Mean retinal thickness on two Optical Coherence Tomography (OCT) measurements ≥250
             microns in the central subfield.

          4. Media clarity, pupillary dilation, and patient cooperation sufficient for adequate
             fundus photographs.

             Exclusion

          5. Macular edema is considered to be due to a cause other than diabetic macular edema.

          6. An ocular condition is present such that, in the opinion of the investigator, visual
             acuity would not improve from resolution of macular edema (e.g., foveal atrophy,
             pigmentary changes, dense subfoveal hard exudates, nonretinal condition).

          7. An ocular condition is present (other than diabetes) that, in the opinion of the
             investigator, might affect macular edema or alter visual acuity during the course of
             the study (e.g., vein occlusion, uveitis or other ocular inflammatory disease,
             neovascular glaucoma, Irvine-Gass Syndrome, etc.)

          8. Substantial cataract that, in the opinion of the investigator, is likely to be
             decreasing visual acuity by 3 lines or more (i.e., cataract would be reducing acuity
             to 20/40 or worse if eye was otherwise normal).

          9. History of prior treatment with intravitreal corticosteroids.

         10. History of peribulbar steroid injection within 6 months prior to randomization.

         11. History of focal/grid macular photocoagulation within 15 weeks (3.5 months) prior to
             randomization.Note: Patients are not required to have had prior macular
             photocoagulation to be enrolled. If prior macular photocoagulation has been performed,
             the investigator should believe that the patient may possibly benefit from additional
             photocoagulation.

         12. History of panretinal scatter photocoagulation (PRP) within 4 months prior to
             randomization.

         13. Anticipated need for PRP in the 4 months following randomization.

         14. History of prior pars plana vitrectomy.

         15. History of major ocular surgery (including cataract extraction, scleral buckle, any
             intraocular surgery, etc.) within prior 6 months or anticipated within the next 6
             months following randomization.

         16. History of YAG capsulotomy performed within 2 months prior to randomization.

         17. Intraocular pressure ≥25 mmHg.

         18. History of open-angle glaucoma (either primary open-angle glaucoma or other cause of
             open-angle glaucoma.) Note: Angle-closure glaucoma is not an exclusion. A history of
             ocular hypertension is not an exclusion as long as (1) intraocular pressure (IOP) is
             &lt;25 mm Hg, (2) the patient is using no more than one topical glaucoma medication, (3)
             the most recent visual field, performed within the last 12 months, is normal (if
             abnormalities are present on the visual field they must be attributable to the
             patient's diabetic retinopathy), and (4) the optic disc does not appear glaucomatous.
             If the intraocular pressure is 22 to &lt;25 mm Hg, then the above criteria for ocular
             hypertension eligibility must be met.

         19. History of steroid-induced intraocular pressure elevation that required IOP-lowering
             treatment.

         20. History of prior herpetic ocular infection.

         21. Exam evidence of ocular toxoplasmosis.

         22. Aphakia.

         23. Exam evidence of pseudoexfoliation.

         24. Exam evidence of external ocular infection, including conjunctivitis, chalazion, or
             significant blepharitis.

        In patients with only one eye meeting criteria to be a study eye at the time of
        randomization, the fellow eye must meet the following criteria:

          1. Best corrected e-ETDRS visual acuity score ≥19 letters (i.e., 20/400 or better).

          2. No prior treatment with intravitreal corticosteroids.

          3. Intraocular pressure &lt; 25 mmHg.

          4. No history of open-angle glaucoma (either primary open-angle glaucoma or other cause
             of open-angle glaucoma.)Note: Angle-closure glaucoma is not an exclusion. A history of
             ocular hypertension is not an exclusion as long as (1) intraocular pressure is &lt;25
             mmHg, (2) the patient is using no more than one topical glaucoma medication, (3) the
             most recent visual field, performed within the last 12 months, is normal (if
             abnormalities are present on the visual field they must be attributable to the
             patient's diabetic retinopathy), and (4) the optic disc does not appear glaucomatous.
             If the intraocular pressure is 22 to &lt;25 mmHg, then the above criteria for ocular
             hypertension eligibility must be met.

          5. No history of steroid-induced intraocular pressure elevation that required
             IOP-lowering treatment.

          6. No exam evidence of pseudoexfoliation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Ip, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>University of Wisconsin Medical School</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jones Eye Institute/University of Arkansas for Medical Sciences</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205-7199</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SCPMG Regional Offices - Kaiser Permanente</name>
      <address>
        <city>Baldwin Park</city>
        <state>California</state>
        <zip>91706</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina-Vitreous Associates Medical Group</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California, Irvine</name>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <zip>92697</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Loma Linda University Health Care, Dept. of Ophthalmology</name>
      <address>
        <city>Loma Linda</city>
        <state>California</state>
        <zip>92354</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Doheny Eye Institute</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jules Stein Eye Institute</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southern California Desert Retina Consultants, MC</name>
      <address>
        <city>Palm Springs</city>
        <state>California</state>
        <zip>92262</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West Coast Retina Medical Group, Inc.</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orange County Retina Medical Group</name>
      <address>
        <city>Santa Ana</city>
        <state>California</state>
        <zip>92705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>California Retina Consultants</name>
      <address>
        <city>Santa Barbara</city>
        <state>California</state>
        <zip>93103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bay Area Retina Associates</name>
      <address>
        <city>Walnut Creek</city>
        <state>California</state>
        <zip>94598</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Denver Health Medical Center</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eldorado Retina Associates, P.C.</name>
      <address>
        <city>Louisville</city>
        <state>Colorado</state>
        <zip>80027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Connecticut Retina Consultants</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06519-1600</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Connecticut Retina Consultants</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06519</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Ophthalmic Research Institute</name>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <zip>33912</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina Group of Florida</name>
      <address>
        <city>Ft. Lauderdale</city>
        <state>Florida</state>
        <zip>33334</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Florida Retina Institute</name>
      <address>
        <city>Lakeland</city>
        <state>Florida</state>
        <zip>33805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Retina Consultants</name>
      <address>
        <city>Lakeland</city>
        <state>Florida</state>
        <zip>33805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sarasota Retina Institute</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>International Eye Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33603</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southeast Retina Center, P.C.</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30909</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina Consultants of Hawaii, Inc.</name>
      <address>
        <city>Aiea</city>
        <state>Hawaii</state>
        <zip>96701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina Associates of Hawaii, Inc.</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96813</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern Medical Faculty Foundation</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Illinois Retina Associates</name>
      <address>
        <city>Joliet</city>
        <state>Illinois</state>
        <zip>60435</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Raj K. Maturi, M.D., P.C.</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46290</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>John-Kenyon American Eye Institute</name>
      <address>
        <city>New Albany</city>
        <state>Indiana</state>
        <zip>47150</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina and Vitreous Associates of Kentucky</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40509-1802</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Paducah Retinal Center</name>
      <address>
        <city>Paducah</city>
        <state>Kentucky</state>
        <zip>42001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maine Vitreoretinal Consultants</name>
      <address>
        <city>Bangor</city>
        <state>Maine</state>
        <zip>04401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Elman Retina Group, P.A.</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21237</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wilmer Ophthalmological Institute at Johns Hopkins</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287-9277</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Retina Group of Washington</name>
      <address>
        <city>Greenbelt</city>
        <state>Maryland</state>
        <zip>20770-3502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina Consultants of Delmarva, P.A.</name>
      <address>
        <city>Salisbury</city>
        <state>Maryland</state>
        <zip>21801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ophthalmic Consultants of Boston</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Joslin Diabetes Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kresge Eye Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201-1423</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henry Ford Health System, Dept of Ophthalmology and Eye Care Services</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Associated Retinal Consultants</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49546</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vision Research Foundation</name>
      <address>
        <city>Royal Oak</city>
        <state>Michigan</state>
        <zip>48073</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina Center, PA</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Louis University Eye Institute</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barnes Retina Institute</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Delaware Valley Retina Associates</name>
      <address>
        <city>Lawrenceville</city>
        <state>New Jersey</state>
        <zip>08648</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The New York Eye and Ear Infirmary/Faculty Eye Practice</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Rochester</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina Consultants, PLLC</name>
      <address>
        <city>Slingerlands</city>
        <state>New York</state>
        <zip>12159</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina-Vitreous Surgeons of Central New York, PC</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of North Carolina, Dept. of Ophthalmology</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charlotte Eye Ear Nose and Throat Assoc, PA</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Horizon Eye Care, PA</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Forest University Eye Center</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina Associates of Cleveland, Inc.</name>
      <address>
        <city>Beachwood</city>
        <state>Ohio</state>
        <zip>44122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Case Western Reserve University</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>OSU Eye Physicians and Surgeons, LLC.</name>
      <address>
        <city>Dublin</city>
        <state>Ohio</state>
        <zip>43017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dean A. McGee Eye Institute</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina Northwest, PC</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Casey Eye Institute</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Penn State College of Medicine</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania Scheie Eye Institute</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina Consultants</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Palmetto Retina Center</name>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <zip>29169</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carolina Retina Center</name>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <zip>29223</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Black Hills Regional Eye Institute</name>
      <address>
        <city>Rapid City</city>
        <state>South Dakota</state>
        <zip>57701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southeastern Retina Associates, P.C.</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37909</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West Texas Retina Consultants P.A.</name>
      <address>
        <city>Abilene</city>
        <state>Texas</state>
        <zip>79605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Retina Associates</name>
      <address>
        <city>Arlington</city>
        <state>Texas</state>
        <zip>76012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina Research Center</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Retina Associates</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Medical Branch, Dept of Ophthalmology and Visual Sciences</name>
      <address>
        <city>Galveston</city>
        <state>Texas</state>
        <zip>77555-1106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charles A. Garcia, PA &amp; Associates</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77002</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina and Vitreous of Texas</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina Consultants of Houston, PA</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Retina Associates</name>
      <address>
        <city>Lubbock</city>
        <state>Texas</state>
        <zip>79424</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Valley Retina Institute</name>
      <address>
        <city>McAllen</city>
        <state>Texas</state>
        <zip>78503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Retina Consultants</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Washington Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin-Madison, Dept. of Ophthalmology</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical College of Wiconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Bhavsar AR, Ip MS, Glassman AR; DRCRnet and the SCORE Study Groups. The risk of endophthalmitis following intravitreal triamcinolone injection in the DRCRnet and SCORE clinical trials. Am J Ophthalmol. 2007 Sep;144(3):454-6.</citation>
    <PMID>17765429</PMID>
  </results_reference>
  <results_reference>
    <citation>Ip MS, Bressler SB, Antoszyk AN, Flaxel CJ, Kim JE, Friedman SM, Qin H; Diabetic Retinopathy Clinical Research Network. A randomized trial comparing intravitreal triamcinolone and focal/grid photocoagulation for diabetic macular edema: baseline features. Retina. 2008 Jul-Aug;28(7):919-30. doi: 10.1097/IAE.0b013e31818144a7.</citation>
    <PMID>18698292</PMID>
  </results_reference>
  <results_reference>
    <citation>Diabetic Retinopathy Clinical Research Network. A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema. Ophthalmology. 2008 Sep;115(9):1447-9, 1449.e1-10. doi: 10.1016/j.ophtha.2008.06.015. Epub 2008 Jul 26.</citation>
    <PMID>18662829</PMID>
  </results_reference>
  <results_reference>
    <citation>Diabetic Retinopathy Clinical Research Network (DRCR.net), Beck RW, Edwards AR, Aiello LP, Bressler NM, Ferris F, Glassman AR, Hartnett E, Ip MS, Kim JE, Kollman C. Three-year follow-up of a randomized trial comparing focal/grid photocoagulation and intravitreal triamcinolone for diabetic macular edema. Arch Ophthalmol. 2009 Mar;127(3):245-51. doi: 10.1001/archophthalmol.2008.610.</citation>
    <PMID>19273785</PMID>
  </results_reference>
  <results_reference>
    <citation>Aiello LP, Edwards AR, Beck RW, Bressler NM, Davis MD, Ferris F, Glassman AR, Ip MS, Miller KM; Diabetic Retinopathy Clinical Research Network. Factors associated with improvement and worsening of visual acuity 2 years after focal/grid photocoagulation for diabetic macular edema. Ophthalmology. 2010 May;117(5):946-53. doi: 10.1016/j.ophtha.2009.10.002. Epub 2010 Feb 1.</citation>
    <PMID>20122739</PMID>
  </results_reference>
  <results_reference>
    <citation>Bressler NM, Edwards AR, Beck RW, Flaxel CJ, Glassman AR, Ip MS, Kollman C, Kuppermann BD, Stone TW; Diabetic Retinopathy Clinical Research Network. Exploratory analysis of diabetic retinopathy progression through 3 years in a randomized clinical trial that compares intravitreal triamcinolone acetonide with focal/grid photocoagulation. Arch Ophthalmol. 2009 Dec;127(12):1566-71. doi: 10.1001/archophthalmol.2009.308.</citation>
    <PMID>20008708</PMID>
  </results_reference>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 3, 2006</study_first_submitted>
  <study_first_submitted_qc>August 18, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 22, 2006</study_first_posted>
  <results_first_submitted>July 14, 2009</results_first_submitted>
  <results_first_submitted_qc>June 4, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 9, 2010</results_first_posted>
  <last_update_submitted>August 25, 2016</last_update_submitted>
  <last_update_submitted_qc>August 25, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 26, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>diabetic</keyword>
  <keyword>macular</keyword>
  <keyword>edema</keyword>
  <keyword>intravitreal</keyword>
  <keyword>triamcinolone</keyword>
  <keyword>laser</keyword>
  <keyword>photocoagulation</keyword>
  <keyword>DME</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Edema</mesh_term>
    <mesh_term>Macular Edema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Triamcinolone hexacetonide</mesh_term>
    <mesh_term>Triamcinolone</mesh_term>
    <mesh_term>Triamcinolone Acetonide</mesh_term>
    <mesh_term>Triamcinolone diacetate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Eighty-eight academic and community based sites across the United States recruited 693 subjects from May 2004 to July 2006.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Focal/Grid Laser Photocoagulation</title>
          <description>Standard of care group: conventional treatment consisting of focal/grid photocoagulation.</description>
        </group>
        <group group_id="P2">
          <title>1mg Intravitreal Triamcinolone</title>
          <description>Intravitreal injection of 1mg of triamcinolone acetonide</description>
        </group>
        <group group_id="P3">
          <title>4 mg Intravitreal Triamcinolone</title>
          <description>Intravitreal injection of 4mg of triamcinolone acetonide</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>2 Years</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="330">Number of Eyes</participants>
                <participants group_id="P2" count="256">Number of Eyes</participants>
                <participants group_id="P3" count="254">Number of Eyes</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="272"/>
                <participants group_id="P2" count="220"/>
                <participants group_id="P3" count="205"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="58"/>
                <participants group_id="P2" count="36"/>
                <participants group_id="P3" count="49"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Dropped</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
                <participants group_id="P2" count="19"/>
                <participants group_id="P3" count="33"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Missed visit</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>3 Years</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="143">Since trial ended early, includes only those with potential for 3 year follow-up -excludes deaths</participants>
                <participants group_id="P2" count="116">Since trial ended early, includes only those with potential for 3 year follow-up -excludes deaths</participants>
                <participants group_id="P3" count="116">Since trial ended early, includes only those with potential for 3 year follow-up -excludes deaths</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="115"/>
                <participants group_id="P2" count="93"/>
                <participants group_id="P3" count="98"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="23"/>
                <participants group_id="P3" count="18"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Focal/Grid Laser Photocoagulation</title>
          <description>Standard of care group: conventional treatment consisting of focal/grid photocoagulation.</description>
        </group>
        <group group_id="B2">
          <title>1mg Intravitreal Triamcinolone</title>
          <description>Intravitreal injection of 1mg of triamcinolone acetonide</description>
        </group>
        <group group_id="B3">
          <title>4 mg Intravitreal Triamcinolone</title>
          <description>Intravitreal injection of 4mg of triamcinolone acetonide</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="330"/>
            <count group_id="B2" value="256"/>
            <count group_id="B3" value="254"/>
            <count group_id="B4" value="840"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63" lower_limit="57" upper_limit="69"/>
                    <measurement group_id="B2" value="63" lower_limit="58" upper_limit="70"/>
                    <measurement group_id="B3" value="63" lower_limit="57" upper_limit="69"/>
                    <measurement group_id="B4" value="63" lower_limit="57" upper_limit="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="166"/>
                    <measurement group_id="B2" value="120"/>
                    <measurement group_id="B3" value="125"/>
                    <measurement group_id="B4" value="411"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="164"/>
                    <measurement group_id="B2" value="136"/>
                    <measurement group_id="B3" value="129"/>
                    <measurement group_id="B4" value="429"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="243"/>
                    <measurement group_id="B2" value="186"/>
                    <measurement group_id="B3" value="183"/>
                    <measurement group_id="B4" value="612"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="26"/>
                    <measurement group_id="B4" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="33"/>
                    <measurement group_id="B4" value="106"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>American Indian/Alaskan Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian/other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than 1 race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown/not reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diabetes Type</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Type 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Type 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="316"/>
                    <measurement group_id="B2" value="244"/>
                    <measurement group_id="B3" value="242"/>
                    <measurement group_id="B4" value="802"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>History of ocular hypertension</title>
          <units>Eyes</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Ocular Hypertension</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No Ocular Hypertension</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="327"/>
                    <measurement group_id="B2" value="248"/>
                    <measurement group_id="B3" value="250"/>
                    <measurement group_id="B4" value="825"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Lens status phakic (clinical examination)</title>
          <units>Eyes</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Phakic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="262"/>
                    <measurement group_id="B2" value="203"/>
                    <measurement group_id="B3" value="197"/>
                    <measurement group_id="B4" value="662"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pseudophakic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68"/>
                    <measurement group_id="B2" value="53"/>
                    <measurement group_id="B3" value="57"/>
                    <measurement group_id="B4" value="178"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>OCT cystoid abnormality (questionable or definite)</title>
          <units>Eyes</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>OCT cystoid abnormality (questionable or definite)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="315"/>
                    <measurement group_id="B2" value="243"/>
                    <measurement group_id="B3" value="246"/>
                    <measurement group_id="B4" value="804"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No Evidence</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing/can not grade</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>OCT subretinal fluid present (questionable or definite</title>
          <units>Eyes</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>OCT subretinal fluid present</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="94"/>
                    <measurement group_id="B2" value="64"/>
                    <measurement group_id="B3" value="61"/>
                    <measurement group_id="B4" value="219"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing (or ungradeable)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No OCT subretinal fluid present</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="235"/>
                    <measurement group_id="B2" value="188"/>
                    <measurement group_id="B3" value="192"/>
                    <measurement group_id="B4" value="615"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Prior Panretinal scatter photocoagulation</title>
          <units>Eyes</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Prior Panretinal scatter photocoagulation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="42"/>
                    <measurement group_id="B4" value="135"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No Prior Panretinal scatter photocoagulation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="277"/>
                    <measurement group_id="B2" value="216"/>
                    <measurement group_id="B3" value="212"/>
                    <measurement group_id="B4" value="705"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Prior photocoagulation for diabetic macular edema</title>
          <units>Eyes</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Prior photocoagulation for DME</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="198"/>
                    <measurement group_id="B2" value="154"/>
                    <measurement group_id="B3" value="158"/>
                    <measurement group_id="B4" value="510"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No Prior photocoagulation for DME</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="132"/>
                    <measurement group_id="B2" value="102"/>
                    <measurement group_id="B3" value="96"/>
                    <measurement group_id="B4" value="330"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Retinopathy severity (ETDRS severity scale)</title>
          <description>Early Treatment Diabetic Retinopathy Study (ETDRS) scale. Retinopathy severity data missing for: 12, 8, 10 eyes in the Laser, 1mg and 4mg treatment groups, respectively.</description>
          <units>Eyes</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Microaneurysms only</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mild-moderately severe nonproliferative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="186"/>
                    <measurement group_id="B2" value="156"/>
                    <measurement group_id="B3" value="151"/>
                    <measurement group_id="B4" value="493"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe nonproliferative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="25"/>
                    <measurement group_id="B4" value="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mild to moderate proliferative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="79"/>
                    <measurement group_id="B2" value="56"/>
                    <measurement group_id="B3" value="62"/>
                    <measurement group_id="B4" value="197"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High-risk proliferative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing (ungradeable)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Visual Acuity Categorized by Randomization Strata</title>
          <description>Letter score and approximate Snellen equivalent. Best score is 97, worst is 0.</description>
          <units>Eyes</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>73-60 (20/32-2-20/62)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="189"/>
                    <measurement group_id="B2" value="149"/>
                    <measurement group_id="B3" value="149"/>
                    <measurement group_id="B4" value="487"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>59-36 (&lt;20/631-20/200)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="129"/>
                    <measurement group_id="B2" value="94"/>
                    <measurement group_id="B3" value="92"/>
                    <measurement group_id="B4" value="315"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>35-24 (20/200-20/320)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Central subfield thickness on OCT</title>
          <description>Mean of two baseline scans. Mean CST &lt;250 microns based on RC grading in 15, 7, and 5 eyes for laser, 1 mg, and 4 mg groups, respectively. Missing/ungradable optical coherence tomography or fundus photo data for 1, 2, and 1 eyes for laser, 1 mg, and 4 mg groups, respectively.</description>
          <units>Microns</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="398" lower_limit="329" upper_limit="505"/>
                    <measurement group_id="B2" value="405" lower_limit="327" upper_limit="514"/>
                    <measurement group_id="B3" value="396" lower_limit="323" upper_limit="484"/>
                    <measurement group_id="B4" value="400" lower_limit="323" upper_limit="514"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Duration of Diabetes</title>
          <units>Years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15" lower_limit="9" upper_limit="21"/>
                    <measurement group_id="B2" value="15" lower_limit="9" upper_limit="21"/>
                    <measurement group_id="B3" value="16" lower_limit="10" upper_limit="22"/>
                    <measurement group_id="B4" value="15" lower_limit="9" upper_limit="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HbA1c</title>
          <description>Missing HbA1c data in 64, 46, and 50 in the laser, 1 mg, and 4 mg groups respectively</description>
          <units>Percentage</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.5" lower_limit="6.6" upper_limit="8.5"/>
                    <measurement group_id="B2" value="7.5" lower_limit="6.8" upper_limit="8.4"/>
                    <measurement group_id="B3" value="7.6" lower_limit="6.8" upper_limit="8.8"/>
                    <measurement group_id="B4" value="7.5" lower_limit="6.6" upper_limit="8.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Intraocular pressure</title>
          <units>microns</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16" lower_limit="13" upper_limit="18"/>
                    <measurement group_id="B2" value="16" lower_limit="13" upper_limit="18"/>
                    <measurement group_id="B3" value="16" lower_limit="14" upper_limit="18"/>
                    <measurement group_id="B4" value="16" lower_limit="13" upper_limit="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Retinal volume on OCT</title>
          <description>Missing/ungradeable optical coherence tomography and fundus photo data for the laser, 1mg, and 4 mg groups respectively: 37, 36, 48.</description>
          <units>cubic millimetre</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9.2" lower_limit="7.9" upper_limit="10.6"/>
                    <measurement group_id="B2" value="8.9" lower_limit="7.8" upper_limit="10.5"/>
                    <measurement group_id="B3" value="8.9" lower_limit="7.9" upper_limit="10.0"/>
                    <measurement group_id="B4" value="9.0" lower_limit="7.8" upper_limit="10.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>e-ETDRS visual acuity</title>
          <description>Best corrected visual acuity letter score as measured by a certified tester using an electronic visual acuity testing machine based on the Early Treatment Diabetic Retinopathy Study (ETDRS) method. Best value on the scale 97, worst 0.</description>
          <units>Letter Score</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62" lower_limit="53" upper_limit="67"/>
                    <measurement group_id="B2" value="62" lower_limit="54" upper_limit="67"/>
                    <measurement group_id="B3" value="62" lower_limit="52" upper_limit="67"/>
                    <measurement group_id="B4" value="62" lower_limit="52" upper_limit="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change In Visual Acuity [Measured With Electronic-Early Treatment Diabetic Retinopathy Study (E-ETDRS)]Baseline to 2 Years.</title>
        <description>Change in best correct visual acuity letter score as measured by a certified tester using an electronic visual acuity testing machine based on the Early Treatment Diabetic Retinopathy Study (ETDRS) method. A positive change denotes an improvement. Best value on the scale 97, worst 0.</description>
        <time_frame>Baseline to 2 Years</time_frame>
        <population>The primary analysis included all randomized eyes and followed the intent-to-treat principle.</population>
        <group_list>
          <group group_id="O1">
            <title>Focal/Grid Laser Photocoagulation</title>
            <description>Standard of care group: conventional treatment consisting of focal/grid photocoagulation.</description>
          </group>
          <group group_id="O2">
            <title>1mg Intravitreal Triamcinolone</title>
            <description>Intravitreal injection of 1mg of triamcinolone acetonide</description>
          </group>
          <group group_id="O3">
            <title>4 mg Intravitreal Triamcinolone</title>
            <description>Intravitreal injection of 4mg of triamcinolone acetonide</description>
          </group>
        </group_list>
        <measure>
          <title>Change In Visual Acuity [Measured With Electronic-Early Treatment Diabetic Retinopathy Study (E-ETDRS)]Baseline to 2 Years.</title>
          <description>Change in best correct visual acuity letter score as measured by a certified tester using an electronic visual acuity testing machine based on the Early Treatment Diabetic Retinopathy Study (ETDRS) method. A positive change denotes an improvement. Best value on the scale 97, worst 0.</description>
          <population>The primary analysis included all randomized eyes and followed the intent-to-treat principle.</population>
          <units>Letter score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="330"/>
                <count group_id="O2" value="256"/>
                <count group_id="O3" value="254"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" spread="17"/>
                    <measurement group_id="O2" value="-2" spread="18"/>
                    <measurement group_id="O3" value="-3" spread="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>P values for two group comparisons for difference in mean change.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.02</p_value>
            <method>ANCOVA</method>
            <method_desc>Repeated Measures Model. Adjusted for baseline visual acuity and prior photocoagulation; Accounted for correlated data from subjects with 2 study eyes</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>P Values for 2 group comparisons of difference in mean change</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.002</p_value>
            <method>ANCOVA</method>
            <method_desc>Repeated Measures Model. Adjusted for baseline visual acuity and prior photocoagulation; Accounted for correlated data from subjects with 2 study eyes</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>P Values for 2 group comparisons of difference in mean change</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.49</p_value>
            <method>ANCOVA</method>
            <method_desc>Repeated Measures Model. Adjusted for baseline visual acuity and prior photocoagulation; Accounted for correlated data from subjects with 2 study eyes</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Central Subfield Thickness at 2 Years</title>
        <description>Median central subfield thickness at two-years. Optical coherence Tomography (OCT) images were obtained by a certified operator using the Zeiss Stratus OCT machine. If the automated thickness measurements were judged by the reading center to be inaccurate, center point thickness was measured manually, and this value was used to impute a value for the central subfield.</description>
        <time_frame>2 Years</time_frame>
        <population>Only subjects with an available Optical coherence tomography (OCT) at baseline and 2 years are included in the OCT analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Focal/Grid Laser Photocoagulation</title>
            <description>Standard of care group: conventional treatment consisting of focal/grid photocoagulation.</description>
          </group>
          <group group_id="O2">
            <title>1mg Intravitreal Triamcinolone</title>
            <description>Intravitreal injection of 1mg of triamcinolone acetonide</description>
          </group>
          <group group_id="O3">
            <title>4 mg Intravitreal Triamcinolone</title>
            <description>Intravitreal injection of 4mg of triamcinolone acetonide</description>
          </group>
        </group_list>
        <measure>
          <title>Central Subfield Thickness at 2 Years</title>
          <description>Median central subfield thickness at two-years. Optical coherence Tomography (OCT) images were obtained by a certified operator using the Zeiss Stratus OCT machine. If the automated thickness measurements were judged by the reading center to be inaccurate, center point thickness was measured manually, and this value was used to impute a value for the central subfield.</description>
          <population>Only subjects with an available Optical coherence tomography (OCT) at baseline and 2 years are included in the OCT analysis.</population>
          <units>Microns</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="261"/>
                <count group_id="O2" value="207"/>
                <count group_id="O3" value="193"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="243" spread="148" lower_limit="197" upper_limit="326"/>
                    <measurement group_id="O2" value="305" spread="167" lower_limit="231" upper_limit="406"/>
                    <measurement group_id="O3" value="279" spread="160" lower_limit="228" upper_limit="430"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Median Change in Visual Acuity Baseline to 2 Years</title>
        <description>Change in best correct visual acuity letter score as measured by a certified tester using an electronic visual acuity testing machine based on the Early Treatment Diabetic Retinopathy Study (ETDRS) method. A positive change denotes an improvement.</description>
        <time_frame>Baseline to 2 Years</time_frame>
        <population>The primary analysis included all randomized eyes and followed the intent-to-treat principle.</population>
        <group_list>
          <group group_id="O1">
            <title>Focal/Grid Laser Photocoagulation</title>
            <description>Standard of care group: conventional treatment consisting of focal/grid photocoagulation.</description>
          </group>
          <group group_id="O2">
            <title>1mg Intravitreal Triamcinolone</title>
            <description>Intravitreal injection of 1mg of triamcinolone acetonide</description>
          </group>
          <group group_id="O3">
            <title>4 mg Intravitreal Triamcinolone</title>
            <description>Intravitreal injection of 4mg of triamcinolone acetonide</description>
          </group>
        </group_list>
        <measure>
          <title>Median Change in Visual Acuity Baseline to 2 Years</title>
          <description>Change in best correct visual acuity letter score as measured by a certified tester using an electronic visual acuity testing machine based on the Early Treatment Diabetic Retinopathy Study (ETDRS) method. A positive change denotes an improvement.</description>
          <population>The primary analysis included all randomized eyes and followed the intent-to-treat principle.</population>
          <units>Letter score</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="330"/>
                <count group_id="O2" value="256"/>
                <count group_id="O3" value="254"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="-6" upper_limit="11"/>
                    <measurement group_id="O2" value="1" lower_limit="-11" upper_limit="9"/>
                    <measurement group_id="O3" value="2" lower_limit="-11" upper_limit="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Distribution of Change in Visual Acuity Baseline to 2 Years</title>
        <description>Change in best correct visual acuity letter score as measured by a certified tester using an electronic visual acuity testing machine based on the Early Treatment Diabetic Retinopathy Study (ETDRS) method.</description>
        <time_frame>baseline to 2 years</time_frame>
        <population>The primary analysis included all randomized eyes and followed the intent-to-treat principle</population>
        <group_list>
          <group group_id="O1">
            <title>Focal/Grid Laser Photocoagulation</title>
            <description>Standard of care group: conventional treatment consisting of focal/grid photocoagulation.</description>
          </group>
          <group group_id="O2">
            <title>1mg Intravitreal Triamcinolone</title>
            <description>Intravitreal injection of 1mg of triamcinolone acetonide</description>
          </group>
          <group group_id="O3">
            <title>4 mg Intravitreal Triamcinolone</title>
            <description>Intravitreal injection of 4mg of triamcinolone acetonide</description>
          </group>
        </group_list>
        <measure>
          <title>Distribution of Change in Visual Acuity Baseline to 2 Years</title>
          <description>Change in best correct visual acuity letter score as measured by a certified tester using an electronic visual acuity testing machine based on the Early Treatment Diabetic Retinopathy Study (ETDRS) method.</description>
          <population>The primary analysis included all randomized eyes and followed the intent-to-treat principle</population>
          <units>Percentage of Eyes</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="330"/>
                <count group_id="O2" value="256"/>
                <count group_id="O3" value="254"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>&gt;= 15 letter improvement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>14 to 10 letter improvement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>9 to 5 letter improvement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>same +- 4 letters</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="27"/>
                    <measurement group_id="O3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5-9 letters worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>10-14 letters worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=15 letters worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Proportion with 15-letter or more worsening</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.03</p_value>
            <method>GEE Repeated Measures</method>
            <method_desc>Hochberg procedure used to determine statistical significance.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Proportion with 15-letter or more worsening</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.01</p_value>
            <method>GEE Repeated Measures</method>
            <method_desc>Hochberg procedure used to determine statistical significance.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Proportion with 15-letter or more worsening</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.82</p_value>
            <method>GEE Repeated Measures</method>
            <method_desc>Hochberg procedure used to determine statistical significance.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change in Central Subfield Thickness Baseline to 2 Years</title>
        <description>Overall central subfield change from baseline. Optical coherence Tomography (OCT) images were obtained by a certified operator using the Zeiss Stratus OCT machine. The average of 2 baseline central subfield thickness measurements was used for analysis.If the automated thickness measurements were judged by the reading center to be inaccurate, center point thickness was measured manually, and this value was used to impute a value for the central subfield. Negative change denotes and improvement.</description>
        <time_frame>Baseline to 2 years</time_frame>
        <population>Only subjects with available OCTs at baseline and 2 years are included in the OCT analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Focal/Grid Laser Photocoagulation</title>
            <description>Standard of care group: conventional treatment consisting of focal/grid photocoagulation.</description>
          </group>
          <group group_id="O2">
            <title>1mg Intravitreal Triamcinolone</title>
            <description>Intravitreal injection of 1mg of triamcinolone acetonide</description>
          </group>
          <group group_id="O3">
            <title>4 mg Intravitreal Triamcinolone</title>
            <description>Intravitreal injection of 4mg of triamcinolone acetonide</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in Central Subfield Thickness Baseline to 2 Years</title>
          <description>Overall central subfield change from baseline. Optical coherence Tomography (OCT) images were obtained by a certified operator using the Zeiss Stratus OCT machine. The average of 2 baseline central subfield thickness measurements was used for analysis.If the automated thickness measurements were judged by the reading center to be inaccurate, center point thickness was measured manually, and this value was used to impute a value for the central subfield. Negative change denotes and improvement.</description>
          <population>Only subjects with available OCTs at baseline and 2 years are included in the OCT analysis.</population>
          <units>Microns</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="261"/>
                <count group_id="O2" value="207"/>
                <count group_id="O3" value="193"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-139" spread="148"/>
                    <measurement group_id="O2" value="-86" spread="167"/>
                    <measurement group_id="O3" value="-77" spread="160"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>P value not adjusted for multiple comparisons</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <method_desc>Repeated Measures Model. Accounted for correlated data from subjects with 2 study eyes; included baseline central subfield thickness as a covariate.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>P Value not adjusted for multiple comparisons</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <method_desc>Repeated Measures Model. Accounted for correlated data from subjects with 2 study eyes; included baseline central subfield thickness as a covariate.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>P Values not adjusted for multiple comparisons</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.91</p_value>
            <method>ANCOVA</method>
            <method_desc>Repeated Measures Model. Accounted for correlated data from subjects with 2 study eyes; included baseline central subfield thickness as a covariate.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Change in Central Subfield Thickness Baseline to 2 Years</title>
        <description>Overall central subfield change from baseline. Optical coherence Tomography (OCT) images were obtained by a certified operator using the Zeiss Stratus OCT machine. The average of 2 baseline central subfield thickness measurements was used for analysis.If the automated thickness measurements were judged by the reading center to be inaccurate, center point thickness was measured manually, and this value was used to impute a value for the central subfield. Negative change denotes an improvement.</description>
        <time_frame>Baseline to 2 Years</time_frame>
        <population>Only subjects with an available OCT's at baseline and 2 years are included in the OCT analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Focal/Grid Laser Photocoagulation</title>
            <description>Standard of care group: conventional treatment consisting of focal/grid photocoagulation.</description>
          </group>
          <group group_id="O2">
            <title>1mg Intravitreal Triamcinolone</title>
            <description>Intravitreal injection of 1mg of triamcinolone acetonide</description>
          </group>
          <group group_id="O3">
            <title>4 mg Intravitreal Triamcinolone</title>
            <description>Intravitreal injection of 4mg of triamcinolone acetonide</description>
          </group>
        </group_list>
        <measure>
          <title>Median Change in Central Subfield Thickness Baseline to 2 Years</title>
          <description>Overall central subfield change from baseline. Optical coherence Tomography (OCT) images were obtained by a certified operator using the Zeiss Stratus OCT machine. The average of 2 baseline central subfield thickness measurements was used for analysis.If the automated thickness measurements were judged by the reading center to be inaccurate, center point thickness was measured manually, and this value was used to impute a value for the central subfield. Negative change denotes an improvement.</description>
          <population>Only subjects with an available OCT's at baseline and 2 years are included in the OCT analysis.</population>
          <units>Microns</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="261"/>
                <count group_id="O2" value="207"/>
                <count group_id="O3" value="193"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-131" lower_limit="-217" upper_limit="-49"/>
                    <measurement group_id="O2" value="-74" lower_limit="-168" upper_limit="-3"/>
                    <measurement group_id="O3" value="-76" lower_limit="-175" upper_limit="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Central Subfield Thickening Decreased by &gt;=50% Baseline to 2 Years</title>
        <description>Overall central subfield change from baseline. Optical coherence Tomography (OCT) images were obtained by a certified operator using the Zeiss Stratus OCT machine. If the automated thickness measurements were judged by the reading center to be inaccurate, center point thickness was measured manually, and this value was used to impute a value for the central subfield.</description>
        <time_frame>Baseline to 2 Years</time_frame>
        <population>Only subjects with available OCTs at baseline and 2 years are included in the OCT analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Focal/Grid Laser Photocoagulation</title>
            <description>Standard of care group: conventional treatment consisting of focal/grid photocoagulation.</description>
          </group>
          <group group_id="O2">
            <title>1mg Intravitreal Triamcinolone</title>
            <description>Intravitreal injection of 1mg of triamcinolone acetonide</description>
          </group>
          <group group_id="O3">
            <title>4 mg Intravitreal Triamcinolone</title>
            <description>Intravitreal injection of 4mg of triamcinolone acetonide</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Central Subfield Thickening Decreased by &gt;=50% Baseline to 2 Years</title>
          <description>Overall central subfield change from baseline. Optical coherence Tomography (OCT) images were obtained by a certified operator using the Zeiss Stratus OCT machine. If the automated thickness measurements were judged by the reading center to be inaccurate, center point thickness was measured manually, and this value was used to impute a value for the central subfield.</description>
          <population>Only subjects with available OCTs at baseline and 2 years are included in the OCT analysis.</population>
          <units>Percentage of Eyes</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="261"/>
                <count group_id="O2" value="207"/>
                <count group_id="O3" value="193"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67"/>
                    <measurement group_id="O2" value="46"/>
                    <measurement group_id="O3" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>P Values not adjusted for multiple comparisons</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>GEE Repeated Measures</method>
            <method_desc>Accounted for correlated data from subjects with 2 study eyes; included baseline central subfield thickness as a covariate.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>P Values not adjusted for multiple comparisons</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>GEE Repeated Measures</method>
            <method_desc>Accounted for correlated data from subjects with 2 study eyes; included baseline central subfield thickness as a covariate.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>P Value not adjusted for multiple comparisons</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.60</p_value>
            <method>GEE Repeated Measures</method>
            <method_desc>Accounted for correlated data from subjects with 2 study eyes; included baseline central subfield thickness as a covariate.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Central Subfield Thickness &lt; 250 Microns at 2 Years</title>
        <description>Overall central subfield change from baseline. Optical coherence Tomography (OCT) images were obtained by a certified operator using the Zeiss Stratus OCT machine. If the automated thickness measurements were judged by the reading center to be inaccurate, center point thickness was measured manually, and this value was used to impute a value for the central subfield.</description>
        <time_frame>2 Years</time_frame>
        <population>Only subjects with available OCTs at baseline and 2 years are included in the OCT analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Focal/Grid Laser Photocoagulation</title>
            <description>Standard of care group: conventional treatment consisting of focal/grid photocoagulation.</description>
          </group>
          <group group_id="O2">
            <title>1mg Intravitreal Triamcinolone</title>
            <description>Intravitreal injection of 1mg of triamcinolone acetonide</description>
          </group>
          <group group_id="O3">
            <title>4 mg Intravitreal Triamcinolone</title>
            <description>Intravitreal injection of 4mg of triamcinolone acetonide</description>
          </group>
        </group_list>
        <measure>
          <title>Central Subfield Thickness &lt; 250 Microns at 2 Years</title>
          <description>Overall central subfield change from baseline. Optical coherence Tomography (OCT) images were obtained by a certified operator using the Zeiss Stratus OCT machine. If the automated thickness measurements were judged by the reading center to be inaccurate, center point thickness was measured manually, and this value was used to impute a value for the central subfield.</description>
          <population>Only subjects with available OCTs at baseline and 2 years are included in the OCT analysis.</population>
          <units>Percentage of Eyes</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="261"/>
                <count group_id="O2" value="207"/>
                <count group_id="O3" value="193"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53"/>
                    <measurement group_id="O2" value="34"/>
                    <measurement group_id="O3" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>P Values not adjusted for multiple comparisons</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>GEE Repeated Measures</method>
            <method_desc>Accounted for correlated data from subjects with 2 study eyes; included baseline central subfield thickness as a covariate.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>P Value not adjusted for statistical analysis</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>GEE Repeated Measures</method>
            <method_desc>Accounted for correlated data from subjects with 2 study eyes; included baseline central subfield thickness as a covariate.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>P Value not adjusted for statistical analysis</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.55</p_value>
            <method>GEE Repeated Measures</method>
            <method_desc>Accounted for correlated data from subjects with 2 study eyes; included baseline central subfield thickness as a covariate.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Visual Acuity From Baseline to 3 Years</title>
        <description>Change in best correct visual acuity letter score as measured by a certified tester using an electronic visual acuity testing machine based on the Early Treatment Diabetic Retinopathy Study (ETDRS) method. A positive change denotes an improvement.</description>
        <time_frame>Baseline to 3 year</time_frame>
        <population>The study discontinued early. Only subjects with 3 years data are included in 3 year analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Focal/Grid Laser Photocoagulation</title>
            <description>Standard of care group: conventional treatment consisting of focal/grid photocoagulation.</description>
          </group>
          <group group_id="O2">
            <title>1mg Intravitreal Triamcinolone</title>
            <description>Intravitreal injection of 1mg of triamcinolone acetonide</description>
          </group>
          <group group_id="O3">
            <title>4 mg Intravitreal Triamcinolone</title>
            <description>Intravitreal injection of 4mg of triamcinolone acetonide</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Visual Acuity From Baseline to 3 Years</title>
          <description>Change in best correct visual acuity letter score as measured by a certified tester using an electronic visual acuity testing machine based on the Early Treatment Diabetic Retinopathy Study (ETDRS) method. A positive change denotes an improvement.</description>
          <population>The study discontinued early. Only subjects with 3 years data are included in 3 year analysis.</population>
          <units>Letter Score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="115"/>
                <count group_id="O2" value="93"/>
                <count group_id="O3" value="98"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5" spread="17"/>
                    <measurement group_id="O2" value="0" spread="16"/>
                    <measurement group_id="O3" value="0" spread="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Visual Acuity From Baseline to 3 Years</title>
        <description>Change in best correct visual acuity letter score as measured by a certified tester using an electronic visual acuity testing machine based on the Early Treatment Diabetic Retinopathy Study (ETDRS) method. A positive change denotes an improvement. Best Value on the scale=97, Worst Value=0</description>
        <time_frame>Baseline to 3 year</time_frame>
        <population>The study discontinued early. Only subjects with 3 years data are included in 3 year analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Focal/Grid Laser Photocoagulation</title>
            <description>Standard of care group: conventional treatment consisting of focal/grid photocoagulation.</description>
          </group>
          <group group_id="O2">
            <title>1mg Intravitreal Triamcinolone</title>
            <description>Intravitreal injection of 1mg of triamcinolone acetonide</description>
          </group>
          <group group_id="O3">
            <title>4 mg Intravitreal Triamcinolone</title>
            <description>Intravitreal injection of 4mg of triamcinolone acetonide</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Visual Acuity From Baseline to 3 Years</title>
          <description>Change in best correct visual acuity letter score as measured by a certified tester using an electronic visual acuity testing machine based on the Early Treatment Diabetic Retinopathy Study (ETDRS) method. A positive change denotes an improvement. Best Value on the scale=97, Worst Value=0</description>
          <population>The study discontinued early. Only subjects with 3 years data are included in 3 year analysis.</population>
          <units>Letter Score</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="115"/>
                <count group_id="O2" value="93"/>
                <count group_id="O3" value="98"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8" lower_limit="-2" upper_limit="15"/>
                    <measurement group_id="O2" value="2" lower_limit="-11" upper_limit="9"/>
                    <measurement group_id="O3" value="4" lower_limit="-8" upper_limit="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Distribution of Visual Acuity Change Baseline to 3 Years</title>
        <description>Change in best correct visual acuity letter score as measured by a certified tester using an electronic visual acuity testing machine based on the Early Treatment Diabetic Retinopathy Study (ETDRS) method. A positive change denotes an improvement. Best value on the scale=97, worst=0</description>
        <time_frame>Baseline to 3 years</time_frame>
        <population>The study discontinued early. Only subjects with 3 years data are included in 3 year analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Focal/Grid Laser Photocoagulation</title>
            <description>Standard of care group: conventional treatment consisting of focal/grid photocoagulation.</description>
          </group>
          <group group_id="O2">
            <title>1mg Intravitreal Triamcinolone</title>
            <description>Intravitreal injection of 1mg of triamcinolone acetonide</description>
          </group>
          <group group_id="O3">
            <title>4 mg Intravitreal Triamcinolone</title>
            <description>Intravitreal injection of 4mg of triamcinolone acetonide</description>
          </group>
        </group_list>
        <measure>
          <title>Distribution of Visual Acuity Change Baseline to 3 Years</title>
          <description>Change in best correct visual acuity letter score as measured by a certified tester using an electronic visual acuity testing machine based on the Early Treatment Diabetic Retinopathy Study (ETDRS) method. A positive change denotes an improvement. Best value on the scale=97, worst=0</description>
          <population>The study discontinued early. Only subjects with 3 years data are included in 3 year analysis.</population>
          <units>Percentage of Eyes</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="115"/>
                <count group_id="O2" value="93"/>
                <count group_id="O3" value="98"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>&gt;= 15 letters better</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>10-14 letters better</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5-9 letters better</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>no change, + - 4 letters</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="23"/>
                    <measurement group_id="O3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5-9 letters worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>10-14 letters worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=15 letters worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Central Subfield Thickness on Optical Coherence Tomography (OCT) at Three Years</title>
        <description>Overall central subfield change from baseline. Optical coherence Tomography (OCT) images were obtained by a certified operator using the Zeiss Stratus OCT machine. If the automated thickness measurements were judged by the reading center to be inaccurate, center point thickness was measured manually, and this value was used to impute a value for the central subfield.</description>
        <time_frame>3 years</time_frame>
        <population>The study discontinued early. Only subjects with 3 years data are included in 3 year analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Focal/Grid Laser Photocoagulation</title>
            <description>Standard of care group: conventional treatment consisting of focal/grid photocoagulation.</description>
          </group>
          <group group_id="O2">
            <title>1mg Intravitreal Triamcinolone</title>
            <description>Intravitreal injection of 1mg of triamcinolone acetonide</description>
          </group>
          <group group_id="O3">
            <title>4 mg Intravitreal Triamcinolone</title>
            <description>Intravitreal injection of 4mg of triamcinolone acetonide</description>
          </group>
        </group_list>
        <measure>
          <title>Central Subfield Thickness on Optical Coherence Tomography (OCT) at Three Years</title>
          <description>Overall central subfield change from baseline. Optical coherence Tomography (OCT) images were obtained by a certified operator using the Zeiss Stratus OCT machine. If the automated thickness measurements were judged by the reading center to be inaccurate, center point thickness was measured manually, and this value was used to impute a value for the central subfield.</description>
          <population>The study discontinued early. Only subjects with 3 years data are included in 3 year analysis.</population>
          <units>Microns</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="111"/>
                <count group_id="O2" value="87"/>
                <count group_id="O3" value="89"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="211" lower_limit="175" upper_limit="271"/>
                    <measurement group_id="O2" value="269" lower_limit="210" upper_limit="299"/>
                    <measurement group_id="O3" value="248" lower_limit="195" upper_limit="342"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Central Subfield Thickness on OCT Baseline to 3 Years</title>
        <description>Overall central subfield change from baseline. Optical coherence Tomography (OCT) images were obtained by a certified operator using the Zeiss Stratus OCT machine. The average of 2 baseline central subfield thickness measurements was used for analysis.If the automated thickness measurements were judged by the reading center to be inaccurate, center point thickness was measured manually, and this value was used to impute a value for the central subfield. Negative change denotes an improvement.</description>
        <time_frame>Baseline to 3 years</time_frame>
        <population>The study discontinued early. Only subjects with 3 years data are included in 3 year analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Focal/Grid Laser Photocoagulation</title>
            <description>Standard of care group: conventional treatment consisting of focal/grid photocoagulation.</description>
          </group>
          <group group_id="O2">
            <title>1mg Intravitreal Triamcinolone</title>
            <description>Intravitreal injection of 1mg of triamcinolone acetonide</description>
          </group>
          <group group_id="O3">
            <title>4 mg Intravitreal Triamcinolone</title>
            <description>Intravitreal injection of 4mg of triamcinolone acetonide</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Central Subfield Thickness on OCT Baseline to 3 Years</title>
          <description>Overall central subfield change from baseline. Optical coherence Tomography (OCT) images were obtained by a certified operator using the Zeiss Stratus OCT machine. The average of 2 baseline central subfield thickness measurements was used for analysis.If the automated thickness measurements were judged by the reading center to be inaccurate, center point thickness was measured manually, and this value was used to impute a value for the central subfield. Negative change denotes an improvement.</description>
          <population>The study discontinued early. Only subjects with 3 years data are included in 3 year analysis.</population>
          <units>Microns</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="111"/>
                <count group_id="O2" value="87"/>
                <count group_id="O3" value="89"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-175" spread="149"/>
                    <measurement group_id="O2" value="-124" spread="184"/>
                    <measurement group_id="O3" value="-126" spread="159"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Central Subfield Thickness on OCT Baseline to 3 Years</title>
        <description>Overall central subfield change from baseline. Optical coherence Tomography (OCT) images were obtained by a certified operator using the Zeiss Stratus OCT machine. The average of 2 baseline central subfield thickness measurements was used for analysis.If the automated thickness measurements were judged by the reading center to be inaccurate, center point thickness was measured manually, and this value was used to impute a value for the central subfield. Negative change denotes an improvement.</description>
        <time_frame>baseline to 3 years</time_frame>
        <population>The study discontinued early. Only subjects with 3 years data are included in 3 year analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Focal/Grid Laser Photocoagulation</title>
            <description>Standard of care group: conventional treatment consisting of focal/grid photocoagulation.</description>
          </group>
          <group group_id="O2">
            <title>1mg Intravitreal Triamcinolone</title>
            <description>Intravitreal injection of 1mg of triamcinolone acetonide</description>
          </group>
          <group group_id="O3">
            <title>4 mg Intravitreal Triamcinolone</title>
            <description>Intravitreal injection of 4mg of triamcinolone acetonide</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Central Subfield Thickness on OCT Baseline to 3 Years</title>
          <description>Overall central subfield change from baseline. Optical coherence Tomography (OCT) images were obtained by a certified operator using the Zeiss Stratus OCT machine. The average of 2 baseline central subfield thickness measurements was used for analysis.If the automated thickness measurements were judged by the reading center to be inaccurate, center point thickness was measured manually, and this value was used to impute a value for the central subfield. Negative change denotes an improvement.</description>
          <population>The study discontinued early. Only subjects with 3 years data are included in 3 year analysis.</population>
          <units>Microns</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="111"/>
                <count group_id="O2" value="87"/>
                <count group_id="O3" value="89"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-158" lower_limit="-273" upper_limit="-75"/>
                    <measurement group_id="O2" value="-103" lower_limit="-248" upper_limit="4"/>
                    <measurement group_id="O3" value="-114" lower_limit="-224" upper_limit="-50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Eyes With a Change in Central Subfield Thickness on OCT &lt;250 Microns From Baseline to 3 Years</title>
        <description>Overall central subfield change from baseline. Optical coherence Tomography (OCT) images were obtained by a certified operator using the Zeiss Stratus OCT machine. The average of 2 baseline central subfield thickness measurements was used for analysis.If the automated thickness measurements were judged by the reading center to be inaccurate, center point thickness was measured manually, and this value was used to impute a value for the central subfield. Negative change denotes an improvement.</description>
        <time_frame>Baseline to 3 years</time_frame>
        <population>The study discontinued early. Only subjects with 3 years data are included in 3 year analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Focal/Grid Laser Photocoagulation</title>
            <description>Standard of care group: conventional treatment consisting of focal/grid photocoagulation.</description>
          </group>
          <group group_id="O2">
            <title>1mg Intravitreal Triamcinolone</title>
            <description>Intravitreal injection of 1mg of triamcinolone acetonide</description>
          </group>
          <group group_id="O3">
            <title>4 mg Intravitreal Triamcinolone</title>
            <description>Intravitreal injection of 4mg of triamcinolone acetonide</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Eyes With a Change in Central Subfield Thickness on OCT &lt;250 Microns From Baseline to 3 Years</title>
          <description>Overall central subfield change from baseline. Optical coherence Tomography (OCT) images were obtained by a certified operator using the Zeiss Stratus OCT machine. The average of 2 baseline central subfield thickness measurements was used for analysis.If the automated thickness measurements were judged by the reading center to be inaccurate, center point thickness was measured manually, and this value was used to impute a value for the central subfield. Negative change denotes an improvement.</description>
          <population>The study discontinued early. Only subjects with 3 years data are included in 3 year analysis.</population>
          <units>Percentage of Eyes</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="111"/>
                <count group_id="O2" value="87"/>
                <count group_id="O3" value="89"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68"/>
                    <measurement group_id="O2" value="43"/>
                    <measurement group_id="O3" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Focal/Grid Laser Photocoagulation</title>
          <description>Standard of care group: conventional treatment consisting of focal/grid photocoagulation.</description>
        </group>
        <group group_id="E2">
          <title>1mg Intravitreal Triamcinolone</title>
          <description>Intravitreal injection of 1mg of triamcinolone acetonide</description>
        </group>
        <group group_id="E3">
          <title>4 mg Intravitreal Triamcinolone</title>
          <description>Intravitreal injection of 4mg of triamcinolone acetonide</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (11.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="135" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="69" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="54" subjects_at_risk="254"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Blood count abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Blood electrolytes decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Blood glucose abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Blood glucose decreased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Blood glucose increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Haemolytic anaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Normochromic normocytic anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Atrioventricular block</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Heart rate increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Heart rate irregular</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Pulse absent</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Diabetic coma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Diabetic complications</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Hyperparathyroidism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blindness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Diabetic retinopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Visual acuity reduced</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Vitreous floaters</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Crohn's disease</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Diverticulum</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Gastric bypass</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Gastrointestinal infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Gastrointestinal injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Impaired gastric emptying</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Lower gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Abdominal hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Colostomy closure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Generalised oedema</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Intermittent claudication</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Limb injury</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>oedema</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Shunt malfunction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Tobacco abuse</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Localised infection</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Post procedural infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Pseudomonas infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Skin bacterial infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Volvulus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Wound infection staphylococcal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Thermal burn</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Compression fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Joint swelling</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Knee arthroplasty</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Lumbar spinal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Meniscus lesion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Pelvic fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Spinal compression fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Colonoscopy abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Oesophageal carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Hydrocephalus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Dementia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Mental disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Psychotic disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Vascular dementia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Bladder transitional cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Dialysis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Kidney infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Nephropathy toxic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Nephrotic syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Renal disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Renal failure chronic</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Renal impairment</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Renal transplant</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Renal vessel disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Urinary incontinence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Urinary tract disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Epididymitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Ovarian cancer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Ovarian cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Prostate examination abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="254"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute respiratory distress syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Asbestosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Bronchitis viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Sleep apnoea syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Allergy to arthropod bite</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Skin ulcer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Limb operation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Metatarsal excision</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Skin lesion excision</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Stent placement</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Surgical vascular shunt</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Toe amputation</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Vitrectomy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Angioplasty</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Arterial occlusive disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis coronary artery</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Carotid artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Coronary arterial stent insertion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Endarterectomy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Iliac artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="69" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="98" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="163" subjects_at_risk="254"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Hypercholesterolaemia</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="254"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac Failure Congestive</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="254"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Anterior Chamber Cell</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="57" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Cataract Cortical</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="32" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Cataract Nuclear</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="38" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Cataract Operation</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="31" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Cataract Subcapsular</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="54" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="75" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Conjunctival Hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="96" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="105" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Diabetic Retinopathy</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Dry Eye</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Eye Irritation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Eye Pain</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="33" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Eye Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Foreign body in the eye</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="61" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="51" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Intraocular Pressure increased</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="50" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="97" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Lacrimation increased</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Maculopathy</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="31" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Vision Blurred</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="44" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="48" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Visual acuity reduced</sub_title>
                <counts group_id="E1" subjects_affected="47" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="51" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Visual disturbance</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Vitreous Detachment</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Vitreous floaters</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="92" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="98" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Vitrous Hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="49" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="43" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="32" subjects_at_risk="254"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Dysonoea</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="254"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="254"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Adam R. Glassman, Director DRCR.net Coordinating Center</name_or_title>
      <organization>Jaeb Center for Health Research</organization>
      <phone>813-975-8690</phone>
      <email>drcrnet@jaeb.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

